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Endometriosis, defined as functioning endo-
metrial glands and stroma outside the uterus, 
is characterized by internal bleeding, inflam-
mation, scarring, and often infertility. The best 
population-based prevalence estimate suggests 
that 8–10% of reproductive-age women in 
the United States have endometriosis; thus, 
> 5.5 million women in North America are 
affected (Eskenazi and Warner 1997). The 
most common symptoms include inter-
menstrual spotting, heavy menstrual bleeding, 
painful cramps (dysmenorrhea), and painful 
intercourse (dyspareunia); women with long-
term, severe endometriosis commonly are 
treated by hysterectomy and oophorectomy. 
Endometriosis develops mainly in reproduc-
tive-age women and typically regresses after 
menopause or oophorectomy, suggesting 
estrogen-dependent growth.
A growing body of literature suggests that 
environmental agents that alter endocrine 
function, either by altering hormone func-
tion or synthesis or by binding to estrogen 
or androgen receptors, may increase endo-
metriosis risk (De Felip et al. 2004; Fierens 
et al. 2003; Heilier et al. 2007; Niskar et al. 
2009; Nisolle et al. 1997; Pauwels et al. 2001; 
Reddy et al. 2006). Polychlorinated biphe-
nyls (PCBs) are endocrine-disrupting agents 
widely used as dielectric fluids in transformers, 
capacitors, and coolants beginning in the early 
1930s. Although PCB production was banned 
in the United States in 1976, PCBs persist in 
the air, water, and soil and have accumulated 
in the fatty tissue of fish, birds, and mammals 
worldwide. As a result, human exposure to 
PCBs occurs primarily through the consump-
tion of animal and dairy products.
The role of human exposure to PCBs in 
the development of hormone-related diseases 
has been addressed in numerous epidemio-
logic studies since the early 1990s. The major-
ity of studies of endometriosis to date have 
focused on dioxin-like PCBs (coplanar PCBs 
that induce biologic effects through binding to 
the aryl hydrocarbon receptor) and have gener-
ally found no association with endometrio-
sis (De Felip et al. 2004; Fierens et al. 2003; 
Heilier et al. 2007; Niskar et al. 2009; Pauwels 
et al. 2001; Reddy et al. 2006). Studies explor-
ing the association of non–dioxin-like PCB 
congeners (non  coplanar PCBs that have no 
or only weak dioxin-like toxicity) and endo-
metriosis risk have been inconsistent, but they 
provide some evidence of association (Gerhard 
and Runnebaum 1992; Lebel et al. 1998; 
Louis et al. 2005; Pauwels et al. 2001; Porpora 
et al. 2006, 2009; Tsukino et al. 2005). The 
most recent of these, an Italian case–control 
study, reported an odds ratio (OR) as high 
as 4.9 for the association between PCB 153 
exposure and endometriosis (Porpora et al. 
2009). The existing studies of non–dioxin-
like PCBs have been primarily small, infer-
tility clinic- or hospital-based investigations 
that have enrolled as cases women undergoing 
ultrasound or surgical evaluation and found to 
have endometriosis. Controls in these studies 
were women who had also undergone ultra-
sound or surgical evaluation but were found 
to be free of endometriosis. To our knowledge 
no population-based study of non–dioxin-like 
PCB exposure and endometriosis risk has been 
conducted. We investigated the role of serum 
noncoplanar PCBs, primarily non–dioxin-like, 
as potential contributors to risk of endometrio-
sis in a large, population-based, case–control 
study of women in Washington State.
Materials and Methods
Study population. Data for this study were 
collected as part of a previously described 
population-based case–control study of endo-
metriosis, Women’s Risk of Endometriosis 
(WREN), conducted within Group Health 
(GH), a large mixed-model health care orga-
nization in the Pacific Northwest (Marino 
et al. 2008). Briefly, cases were female 18- 
to 49-year-old GH enrollees with an inci-
dent endometriosis diagnosis [International 
Classification of Disease, 9th Revision (ICD-9; 
World Health Organization 1977), diagnos-
tic codes 617.0–617.5, 617.8, and 617.9, 
excluding individuals with ICD-9 code 617.0, 
uterine endometriosis, who actually had 
adeno  myosis as determined by the pathology 
report] between 1 April 1996 and 31 March 
2001. The date of each patient’s first GH visit 
for symptoms leading to the endometrio-
sis diagnosis was determined through chart 
review and assigned as the reference date for 
cases. Population-based controls were ran-
domly selected from a list of 18- to 49-year-
old female GH enrollees during the same time 
period as the diagnoses of the cases. Controls 
were frequency matched to cases on 5-year 
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Ba c k g r o u n d: Endometriosis, a gynecologic disorder affecting 8–10% of reproductive-age women in 
the United States, is defined as the presence of endometrial tissue outside the uterus and is linked to 
pelvic pain and infertility. Environmental contaminants, including polychlorinated biphenyls (PCBs), 
are hypothesized to contribute to endometriosis risk through effects on steroid hormones.
oB j e c t i v e: We evaluated serum concentrations of certain noncoplanar PCBs, which have no or 
only weak dioxin-like properties, as risk factors for endometriosis.
Me t h o d s : In a case–control study of Group Health enrollees in western Washington State, 20 PCB 
congeners were measured in serum from surgically confirmed endometriosis cases that were newly 
diagnosed between 1996 and 2001 (n = 251) and from female controls matched for age and reference 
year (n = 538).
re s u l t s: Summed and estrogenic PCB concentrations were not associated with endometriosis risk 
[summed: odds ratio (OR) = 1.3; 95% confidence interval (CI), 0.8–2.2; estrogenic: OR = 1.1; 95% CI, 
0.8–1.4]. Although several congener-specific ORs were statistically above or below the null (PCB 170: 
third quartile vs. lowest: OR = 0.5; 95% CI, 0.3–0.9; PCB 196: third quartile vs. lowest: OR = 0.4; 
95% CI, 0.2–0.7; PCB 201: second vs. lowest: OR = 0.5; 95% CI, 0.3–0.8; third quartile vs. lowest: 
OR = 0.4; 95% CI, 0.2–0.7), there were no overall consistent patterns of endometriosis risk.
co n c l u s i o n s: Taken in context with other North American studies, our findings suggest that non-
coplanar PCB concentrations consistent within the range of exposure currently observed in western 
Washington State do not contribute meaningfully to endometriosis risk.
key w o r d s : case–control, endometriosis, non–dioxin-like PCBs, population-based, risk factors. 
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age intervals, and each was assigned a reference 
date to correspond with the distribution of 
reference dates of the cases. Upon initial tele-
phone eligibility screening, women who did 
not speak English or who reported a hysterec-
tomy or bilateral oophorectomy were excluded 
from participation. All subjects provided 
informed consent and the GH Institutional 
Review Board approved all study protocols.
An interview ascertaining endometriosis 
risk factors was completed by 340 cases (73% 
of those eligible) and 741 controls (73% of 
those eligible). An interviewer asked questions 
from a structured questionnaire to ascertain 
information on exposures occurring prior 
to the reference date; the questionnaire also 
included questions regarding demo  graphics, 
employment, prior medical conditions, men-
strual history, pregnancy history, contraceptive 
methods, hormone use, tobacco and alcohol 
use, and family and personal history of endo-
metriosis. Inpatient and outpatient medical 
records were reviewed for all consenting study 
participants; further, medical records of cases 
were abstracted for symptom type and sever-
ity as well as for endometriosis lesion charac-
teristics. As a result of information captured in 
the interview, 12 cases and 14 controls with a 
prior history of surgically confirmed endometri-
osis but included in the original interview were 
excluded from analysis. We used a published 
case definition that emphasizes more serious 
disease. As a result, the case definition was fur-
ther refined to include only those women with 
definite or probable endometriotic disease—
disease causing structural or functional damage 
or substantial symptoms—or as defined by 
Holt and Weiss (2000). Under these criteria, 
definite endometriotic disease included ovarian 
endometriomas, pelvic endometriotic lesions 
> 5-mm deep, and pelvic endometrio  tic lesions 
with adhesions not attributable to other causes. 
Other endometriotic implants with at least 
one major endometriosis symptom (infertility, 
moderate to severe dysmenor  rhea, dyspare-
unia, or pelvic pain) were classified as probable 
endometriotic disease. As a result, cases with-
out surgical evidence of disease and asympto-
matic cases with super  ficial or ambiguous 
pelvic lesions were excluded (n = 12), as well 
as three cases of extra  pelvic scar endometriosis. 
After the interview, we asked all 1,022 study 
participants who were interviewed in person 
after funding for the PCB assays was obtained 
(93.5% of all cases and 94.6% of all controls) 
to donate 20 mL of blood; 78.7% of these 
cases and 76.5% of these controls agreed to 
participate in the blood draw. Measurement 
of PCB concentrations in serum was com-
pleted for 251 cases and 538 controls, the final   
analysis subset.
PCB measurements. Serum samples from 
the blood draw of each study subject were 
processed at the Fred Hutchinson Cancer 
Research Center and stored in acid-washed 
glass vials at –20°C until shipment on dry ice 
to the laboratory in the Division of Laboratory 
Sciences, National Center for Environmental 
Health, [Centers for Disease Control and 
Prevention (CDC), Atlanta, GA]. All blood 
collection equipment and vials remained 
in their original packaging until use in the 
field. Wet-weight concentrations of 34 PCB 
  congeners [IUPAC (International Union of 
Pure and Applied Chemistry) 18, 28, 44, 
49, 52, 66, 74, 87, 99, 101, 118, 128, 138, 
146, 149, 151, 153, 156, 157, 167, 170, 172, 
177, 178, 180, 183, 187, 189, 194, 195, 196, 
201, 206, and 209] were quantified in serum 
samples by accelerated solvent extraction with 
gel permea  tion chromatography purification 
followed by high-resolution gas chromatog-
raphy/high-resolution mass spectrometry 
with isotope dilution quantification, based on   
methods previously published (Barr et al. 
2003, 2006). The congeners evaluated are 
non  coplanar PCBs, and all are non–dioxin-
like except PCBs 118 and 156, which cause 
only very weak dioxin-like toxicity (Van den 
Berg et al. 1998, 2006). The detection limit 
was 20 pg/g serum for congeners 18 and 28 
and 5.0 pg/g serum for all other congeners.
Free cholesterol, total cholesterol, triglycer-
ides, and phospholipids were measured in each 
serum sample using enzymatic methods (Roche 
Chemicals, Indianapolis, IN) (Phillips et al. 
1989). Total lipid concentrations were calcu-
lated for each sample using published equa-
tions (Bernert et al. 2007; Phillips et al. 1989). 
We adjusted for intra  individual variations in 
serum wet-weight PCB concentrations result-
ing from fluctuations in serum lipid concentra-
tion by including a natural log-transformed 
total lipid variable as an independent variable 
in all statistical analyses.
Statistical analysis. Information on num-
ber of samples with PCB measurements above 
the detection limit is provided in Supplemental 
Material, Table 1 (doi:10.1289/ehp.0901444). 
PCB congeners 87, 101, 128, 146, 149, 151, 
157, 167, 172, 177, 178, 183, 189, and 195 
were detected in < 75% of samples; thus, these 
congeners were excluded from further analy-
ses presented here. Measurement reliability 
was assessed through comparison of 36 ran-
domly selected quality control (QC) dupli-
cates included in each run. The within-batch 
intra  class correlation coefficient (ICC) was 
calculated for each QC pair. The 20 conge-
ners included in our statistical analyses showed 
high reliability, with a median ICC of 0.96 
and all ICCs > 0.90.
We categorized wet-weight PCB concen-
trations according to the quartile distribu-
tion in controls. Values below the limit of 
detection were always included in the lowest 
exposure category, which served as the refer-
ence category. To assess a linear trend of the 
association between endometriosis risk and 
PCB concentration, we also fit models using 
the natural log-transformed continuous values 
for each PCB congener. Values below the 
limit of detection were set to missing for the 
log-linear models.
In addition to separately analyzing indi-
vidual PCB congeners, we created two sum-
mary PCB variables. The sum of the PCB 
congeners (ΣPCBs) in our analysis was com-
puted by first converting the wet-weight PCB 
measure (picograms per gram serum) to moles 
per gram serum and then summing across 
the individual PCB congeners. Conversion to 
moles per gram was accomplished by dividing 
the wet-weight PCB value by the molecular 
weight for each congener. A second summary 
variable, estrogenic PCBs, was formulated by 
summing the molar concentrations of PCB 
congeners 18, 44, 49, 66, 74, and 99, which 
have been observed as having estrogenic 
potency using an assay based on in vitro estro-
gen-dependent proliferation of MCF-7 cells 
(DeCastro et al. 2006). ΣPCBs and estrogenic 
PCB concentrations were categorized into 
quartiles based on the distribution in controls, 
with the lowest category serving as the refer-
ence. To enable summing of PCB congeners 
for the entire study population, values below 
the detection limit were assigned a value of 
the detection limit divided by the square root 
of 2 for each PCB (Hornung and Reed 1990; 
Vo et al. 2008). To evaluate a linear trend, 
continuous models were also fit using the log-
transformed imputed continuous value for 
each summary measure.
ORs and 95% confidence intervals (CIs) 
for the risk of endometriosis in association 
with serum PCB concentrations were esti-
mated using unconditional logistic regression. 
We analyzed variables for each PCB congener 
(as quartile categories or the log-transformed 
continuous variable) or ΣPCB metric in sep-
arate models. All analyses were adjusted for 
the frequency-matching variables (5-year age 
group and year of enrollment), natural log-
transformed total lipid value as a continuous 
variable, and the following confounders based 
on a ≥ 10% change in the beta coefficient for 
at least one quartile of ΣPCBs: alcohol (cur-
rent, former, never use), income (< $35,000, 
$35,000–$69,999, > $70,000; $US) and 
quartile of serum p,p´-dichlorodiphenyl 
dichloro  ethylene (DDE; nanograms per liter). 
DDE was included as an a priori potential 
confounding factor because it was previously 
reported to be associated with endometriosis 
(Porpora et al. 2009), and DDE was modestly 
associated with endometriosis in our study. 
It was retained in the final model because it 
met our criteria for a model-based confounder. 
Other potential confounders considered in 
the models included race (Caucasian, African 
American, Asian American, other), education Trabert et al.
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(< 12 years, 12 years, > 12 years), body mass 
index (BMI; < 25.0 kg/m2, 25.0–29.9 kg/m2,   
≥ 30.0 kg/m2), physical activity (any vs. 
none), age at menarche (< 12 years, 12–13 
years, > 13 years), first-degree family history of 
endometriosis (mother or full sister), history of 
breast-feeding (nulliparous, did not breast-feed, 
breast-fed ≤ 1 month, breast-fed > 1 month), 
smoking (current, former, never use), and 
mari  juana use (current, former, never); how-
ever, these covariates did not satisfy our defini-
tion of a model-based confounding factor and 
were not included in our final models.
Because the inability to become pregnant 
may be a consequence of endometriosis rather 
than a risk factor for the disease, we did not 
include parity as a potential confounding fac-
tor in our analyses. However, we did evaluate 
concentrations of ΣPCBs and estrogenic PCB 
as risk factors for endometriosis within strata 
of nulli  parous and parous women.
Endometriosis is a heterogeneous disease 
entity, and ovarian and nonovarian endo-
metriosis may have different etiologies. 
Therefore, in one sub  analysis, we evaluated 
the association between PCB congeners and 
ovarian endometriosis and non  ovarian pelvic 
endometriosis, separately. We also considered 
separately cases who reported seeking care 
only for reasons other than infertility, because 
women who seek treatment for infertility 
may have endometriosis discovered inciden-
tally as part of the diagnostic process rather 
than because of symptomatic disease. Finally, 
because of the possibility that there may be 
undiagnosed symptomatic cases in our popu-
lation-based control group, we also conducted 
a sub  analysis comparing endometriosis cases 
only with asymptomatic controls.
Data analyses were performed using 
Stata software (Version 10.1 for Windows; 
(StataCorp, College Station, TX). The thresh-
old for significance was set at p ≤ 0.05. The 
study protocol was reviewed and approved by 
the Institutional Review Boards at GH and 
Fred Hutchinson Cancer Research Center.
Results
The distributions of selected demographic and 
health characteristics for the case and control 
women with PCB laboratory measure  ments 
are provided in Table 1. Cases and controls 
were similar with regard to race, education, 
and BMI. A higher percentage of cases than 
controls were current alcohol users (chi-square 
p-value = 0.02). The distribution of demo-
graphic and health characteristics were similar 
for study subjects who did and did not provide 
blood samples (results not shown). The popu-
lation median wet-weight serum PCB con-
centration and the minimum and maximum 
detected concentrations of each PCB congener 
are shown in Supplemental Material, Table 1 
(doi:10.1289/ehp.0901444). For those conge-
ners with > 25% of samples below the limit of 
detection (PCB congeners 87, 101, 128, 149, 
151, 157, 167, 172, 177, 178, 183, and 189), 
the percentage of quantified samples did not 
differ by disease status, nor were the quantified 
PCB congeners associated with endometriosis 
in analyses of categorized PCB concentration 
with observations below the detection limit 
included in the reference category (results not 
shown).
Higher quartiles of ΣPCB concentrations 
and estrogenic PCB concentrations were not 
associated with endometriosis risk (Table 2). 
In congener-specific analyses, modestly elevat-
ed—albeit not statistically significant—ORs 
were observed for PCBs 44, 49, 118, and 138 
in some quartiles (maximum OR = 1.5). We 
observed inverse associa  tions of PCB 170, 
PCB 196, and PCB 201 concentrations with 
endometriosis risk in some quartiles; however, 
there were no overall consistent patterns of 
endometriosis risk with these congeners. Using 
the natural log-transformed continuous PCB 
measures, we found no statistically significant 
log-linear associations with endometriosis risk 
for any of the congeners assessed.
Stratifying on parity, neither ΣPCB nor 
estrogenic PCB concentrations were associ-
ated with endometriosis risk, similar to our 
analysis of all women combined (Table 3). 
Table 1. Demographic and health characteristics of endometriosis cases (n = 251) and controls (n = 538), 
GH, 1996–2001.
Cases Controls
Characteristic n (%)a n (%)a p-Value
Age (years)
18–24 20 (8.0) 44 (8.2)
25–34 52 (20.7) 93 (17.3)
35–44 121 (48.2) 277 (51.5)
45–49 58 (23.1) 124 (23.0)
Race
Caucasian 207 (82.5) 444 (82.5)
African American 8 (3.2) 23 (4.3)
Asian American 13 (5.2) 36 (6.7)
Other 23 (9.2) 34 (6.3) 0.38
Income (US$)
< 35,000 75 (29.9) 146 (27.1)
35,000–69,999 106 (42.2) 223 (41.4)
≥ 70,000 61 (24.3) 153 (28.4) 0.56
Education (years)
< 12 8 (3.2) 17 (3.2)
12 44 (17.5) 96 (17.8)
> 12 199 (79.3) 425 (79.0) 0.99
BMI (kg/m2)
Underweight (< 18.5) 8 (3.2) 10 (1.9)
Normal (18.5–24.9) 127 (50.6) 279 (51.9)
Overweight (25–29.9) 62 (24.7) 140 (26.0)
Obese (≥ 30) 54 (21.5) 105 (19.5) 0.61
Physical activity
Any physical activity 194 (77.3) 429 (79.7)
No physical activity 57 (22.7) 108 (20.1) 0.40
Cigarette smoking
Current 51 (20.3) 89 (16.5)
Former 57 (22.7) 124 (23.0)
Never 143 (57.0) 325 (60.4) 0.42
Alcohol use
Current 214 (50.8) 162 (44.0)
Former 85 (20.2) 73 (19.8)
Never 121 (28.7) 133 (36.1) 0.02
Parity
Nulliparous 122 (48.6) 158 (29.4)
Parous 129 (51.4) 379 (70.4) 0.01
History of breast-feeding among parous women
Did not breast-feed 28 (21.7) 72 (19.1)
≤ 1 month 11 (8.5) 18 (4.8)
> 1 month 90 (69.8) 288 (75.9) 0.20
DDE quartile (ng/L)
≤ 900 56 (22.3) 134 (24.9)
901–1,575 70 (27.9) 135 (25.1)
1,576–2,820 62 (24.7) 135 (25.1)
> 2,820 63 (25.1) 134 (24.9) 0.58
Total DDE (ng/L) median (Q1, Q3) 1569.7 (947.5, 2825.3) 1574.5 (900.0, 2818.2)
Total lipids (mg/dL) median (Q1, Q3) 679.6 (588.5, 814.3) 653.8 (567.3, 769.1)
aNumbers may not sum to column total because of missing data.PCBs and endometriosis risk
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Similarly, individual PCB congeners were 
not associated with endometriosis risk when 
stratified by parity (results not shown). Our 
results were not substantially different when 
restricted to ovarian endometriosis cases only, 
non  ovarian pelvic endometriosis cases only, or 
non–infertility-related case status (results not 
shown). In post hoc analyses excluding DDE 
as a potential confounding factor (because of 
potential collinearity with PCB), there was 
little difference in the overall interpretation 
of the results (results not shown). Compared 
with the results in Tables 2 and 3, the ORs 
were not increased in analyses restricted to 
asymptomatic controls, suggesting that the 
presence of undiagnosed symptomatic cases in 
our control group was unlikely to have affected 
our study (results not shown).
Discussion
To our knowledge, this is the first population-
based case–control study of the association 
between non–dioxin-like PCB concentrations 
and endometriosis. After controlling for age, 
reference year, income, alcohol consumption, 
serum lipids, and serum DDE, we observed 
statistically significant inverse associations for 
PCBs 170, 196, and 201 with endometriosis 
risk. Given the large number of statistical tests 
conducted, we would have expected at least 
three statistically significant associations; thus, 
these quartile associations are likely due to 
chance. Further, these associa  tions have not 
been reported elsewhere, and they did not 
exhibit exposure–response relation  ships that 
would strengthen evidence for causation. The 
ORs calculated using quartiles of ΣPCB and 
estrogenic PCB serum concentrations pro-
vided evidence against an association between 
non–dioxin-like PCBs and endometriosis, 
and the lack of association was consistent 
in both parous and nulli  parous subgroups. 
Additionally, there were no consistent log- 
linear trends in the association between 
ΣPCB-, estrogenic PCB–, or congener-specific   
PCB levels and endometriosis risk.
Several studies have evaluated non–dioxin-
like PCBs and endometrio  sis risk, with incon-
sistent results (Lebel et al. 1998; Louis et al. 
2005; Pauwels et al. 2001; Porpora et al. 2006; 
Reddy et al. 2006; Tsukino et al. 2005). There 
was a suggestion of increased endometriosis risk 
with PCBs 138, 153, and 180 in a German 
study (Gerhard and Runnebaum 1992) and 
in two studies conducted in Rome, Italy, with 
overlapping study populations (Porpora et al. 
2006, 2009), findings that were not replicated 
in our study or in other studies (Lebel et al. 
1998; Louis et al. 2005; Pauwels et al. 2001; 
Tsukino et al. 2005). In the study conducted 
in Germany, Gerhard and Runnebaum (1992) 
reported significantly higher mean serum con-
centrations of PCBs 138, 153, and 180 among 
women with endometriosis (n = 28) compared 
with women without endometriosis (n = 441). 
The authors evaluated PCB and endometrio-
sis risk in a population of women attending a 
medical center at the University of Heidelberg 
for “hormone disturbances” and compared 
mean PCB concentrations in women with 
endometriosis and women without endo-
metriosis. It is unclear whether the presence of 
endometriosis was laparoscopically or histologi-
cally confirmed, and it does not appear that the 
Table 2. ORs (95% CIs) for association between wet‑weight serum PCB congeners (modeled independently) 
and endometriosis, GH, 1996–2001.
Reference Quartile 2 Quartile 3 Quartile 4a Log-linearb
ΣPCBs 44/96c 45/98 42/99 57/95
Adjusted 1.0 0.9 (0.5–1.7) 0.9 (0.5–1.6) 1.2 (0.6–2.3) 1.3 (0.8–2.2)
Estrogenic PCBc  58/116 47/117 57/116 59/116
Adjusted 1.0 0.7 (0.4–1.1) 0.8 (0.5–1.3) 0.9 (0.5–1.4) 1.1 (0.8–1.4)
PCB 18 57/133 67/135 62/132 65/135
Adjusted 1.0 1.1 (0.7–1.7) 1.0 (0.6–1.6) 1.0 (0.7–1.6) 1.0 (0.8–1.2)
PCB 28 57/133 71/137 59/134 64/134
Adjusted 1.0 1.2 (0.8–1.8) 1.0 (0.6–1.5) 1.0 (0.6–1.6) 1.0 (0.8–1.2)
PCB 44 50/125 77/124 57/132 61/123
Adjusted 1.0 1.5 (1.0–2.4) 1.0 (0.6–1.6) 1.2 (0.7–1.9) 1.0 (0.7–1.4)
PCB 49 49/133 71/125 44/125 67/126
Adjusted 1.0 1.4 (0.9–2.2) 0.9 (0.5–1.4) 1.3 (0.8–2.1) 1.1 (0.8–1.5)
PCB 52 58/127 61/128 58/132 68/128
Adjusted 1.0 1.0 (0.6–1.6) 0.9 (0.6–1.4) 1.2 (0.7–1.8) 0.9 (0.7–1.2)
PCB 66 58/134 73/131 57/129 59/132
Adjusted 1.0 1.3 (0.8–2.0) 1.0 (0.6–1.6) 1.0 (0.6–1.5) 1.0 (0.8–1.3)
PCB 74 61/136 48/132 63/134 78/134
Adjusted 1.0 0.8 (0.5–1.3) 1.0 (0.6–1.6) 1.2 (0.7–2.1) 1.2 (0.9–1.7)
PCB 99 51/130 71/130 58/128 65/131
Adjusted 1.0 1.2 (0.7–1.9) 0.8 (0.5–1.5) 1.0 (0.6–1.8) 1.0 (0.7–1.3)
PCB 118 50/129 58/130 74/130 68/130
Adjusted 1.0 1.2 (0.7–1.9) 1.4 (0.9–2.4) 1.3 (0.8–2.3) 1.0 (0.8–1.3)
PCB 138 52/129 72/131 52/131 69/128
Adjusted 1.0 1.4 (0.8–2.2) 0.9 (0.5–1.7) 1.2 (0.7–2.3) 1.0 (0.7–1.4)
PCB 153 58/133 64/132 51/133 73/131
Adjusted 1.0 1.1 (0.7–1.8) 0.8 (0.5–1.5) 1.2 (0.7–2.2) 1.1 (0.8–1.6)
PCB 156 57/122 55/121 39/100 80/143
Adjusted 1.0 0.9 (0.6–1.6) 0.8 (0.5–1.5) 1.1 (0.6–2.0) 1.0 (0.7–1.4)
PCB 170 69/134 57/128 43/126 74/127
Adjusted 1.0 0.8 (0.5–1.2) 0.5 (0.3–0.9)* 0.9 (0.5–1.5) 1.0 (0.7–1.4)
PCB 180 69/132 54/134 57/133 69/133
Adjusted 1.0 0.7 (0.4–1.1) 0.7 (0.4–1.1) 0.8 (0.5–1.4) 0.9 (0.7–1.2)
PCB 187 59/121 57/119 53/125 66/117
Adjusted 1.0 1.2 (0.7–2.0) 1.0 (0.5–1.7) 1.3 (0.7–2.4) 1.0 (0.7–1.4)
PCB 194 67/128 43/120 51/126 66/125
Adjusted 1.0 0.7 (0.4–1.2) 0.7 (0.4–1.2) 0.9 (0.5–1.6) 1.0 (0.7–1.4)
PCB 196 61/122 56/126 40/132 74/123
Adjusted 1.0 0.7 (0.4–1.2) 0.4 (0.2–0.7)* 0.9 (0.5–1.7) 1.0 (0.7–1.3)
PCB 201 70/120 41/125 44/126 73/126
Adjusted 1.0 0.5 (0.3–0.8)* 0.4 (0.2–0.7)* 0.7 (0.4–1.3) 0.9 (0.7–1.3)
PCB 206 61/130 51/120 59/147 65/123
Adjusted 1.0 0.8 (0.5–1.4) 0.7 (0.4–1.3) 1.0 (0.5–1.8) 0.9 (0.7–1.2)
PCB 209 66/114 54/121 58/133 51/123
Adjusted 1.0 0.8 (0.5–1.3) 0.7 (0.4–1.2) 0.7 (0.4–1.2) 0.8 (0.6–1.1)
Values shown are number of cases/number of controls and ORs (95% CIs) adjusted for matching factors, log total serum 
lipids, income, alcohol consumption, and DDE exposure. 
aQuartile cut points are provided in Supplemental Material, Table 1 (doi:10.1289/ehp.0901233). bData from the log‑linear 
continuous model; OR is for a one‑unit increase in the natural log‑transformed wet‑weight PCB (picograms per gram 
serum) concentration. cEstrogenic PCBs include PCB congeners 18, 44, 49, 66, 74, 99. *p < 0.05.
Table 3. ORs (95% CIs) for association of summed and estrogenic serum PCB congeners and endometriosis 
risk, GH, 1996–2001.
Reference Quartile 2 Quartile 3 Quartile 4
p-Value 
interaction
ΣPCBs
Nulliparous women 1.0 1.4 (0.5–3.8) 0.6 (0.2–1.6) 0.9 (0.3–2.6) 0.21
Parous women 1.0 0.7 (0.3–1.6) 0.9 (0.4–2.2) 1.2 (0.5–2.9)
Estrogenic PCBsa
Nulliparous women 1.0 1.4 (0.6–3.2) 1.1 (0.5–2.4) 0.8 (0.4–1.8) 0.16
Parous women 1.0 0.5 (0.2–0.9) 0.6 (0.3–1.2) 0.8 (0.4–1.5)  
Models were adjusted for matching factors, log‑lipids, income, alcohol consumption, and DDE exposure. 
aEstrogenic PCBs include PCB congeners 18, 44, 49, 66, 74, 99.Trabert et al.
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authors adjusted for serum lipids when making 
comparisons.
In the most recent and largest of the two 
Italian studies, Porpora et al. (2009) reported 
significantly elevated concentrations of PCBs 
118, 138, 153, 170, and 180 in cases (n = 80) 
with laparo  scopically diagnosed endometriosis 
compared with the controls (n = 78), nulli-
parous women with benign gynecologic con-
ditions and no evidence of endometriosis. 
In contrast to that study, our study was not 
restricted to nulli  parous women; however, we 
did evaluate our PCB–endometriosis associa-
tions stratified by parity, and our conclusions 
were not substantially different among nulli-
parous women. Our results may have differed 
because our control group was not restricted to 
women under  going laparoscopy; rather, it was 
a random sample of reproductive-age women 
from the GH population. Furthermore, we 
included serum lipids as a covariate in our 
model rather than using lipid-standardized 
PCB concentrations, because the latter may 
be prone to bias, depending on the hypothe-
sized underlying PCB–lipid disease association 
(Schisterman et al. 2005). Finally, differences 
between our results and the study by Porpora 
et al. (2009) may be due to geographic variabil-
ity in PCB concentrations. The lipid-adjusted 
geometric mean PCB congener concentrations 
PCBs 138, 153, and 180 were almost twice 
as high in the control population from Rome 
than in our Washington State control popu-
lation (e.g., the geometric mean concentra-
tion for PCB 153 was 61.8 ng/g lipid in the 
Porpora study, compared with 32.4 ng/g lipid 
among those detected in the present study), 
and it is possible that PCBs contribute to endo-
metriosis risk only at higher concentrations 
than those observed in our study.
The remaining studies that evaluated non–
dioxin-like PCBs and endometrio  sis risk have 
reported a lack of association between ΣPCB 
concentrations and endometriosis risk; although 
they have included PCBs 118, 138, 153, 
and 180, most have not reported congener- 
specific results, further limiting comparison 
among studies (Lebel et al. 1998; Louis et al. 
2005; Pauwels et al. 2001; Tsukino et al. 2005). 
One pilot study conducted at an infertility 
clinic in Belgium (Pauwels et al. 2001) found 
no association of lipid-adjusted concentrations 
of PCB congeners 118, 138, 153, or 180 and 
endometriosis risk, in contrast to the German 
(Gerhard and Runnebaum 1992) and Italian 
studies (Porpora et al. 2006, 2009). The lipid-
adjusted median values of these congeners were 
higher in the Belgian population (Pauwels et al. 
2001) than than those from our study popula-
tion (results not shown). However, the selection 
of infertile controls in the Belgian study may 
have masked an association, if present.
In a recent small U.S. study that adjusted 
for serum lipids as a covariate, as we did, Louis 
et al. (2005) reported no association between 
ΣPCB or estrogenic PCB concentrations and 
endometriosis risk. The study enrolled 84 con-
secutive women under  going laparoscopies at 
two university-affiliated hospitals in Buffalo, 
New York, and compared endometriosis cases 
(n = 32) with women diagnosed with other 
gynecologic pathology or tubal sterilization 
and without endometriosis (n = 52).
The present study has several strengths, 
including its population-based design and large 
sample size. Cases and controls were all mem-
bers of the same health maintenance organi-
zation, eliminating most issues pertaining to 
disparity of access to medi  cal care. Chosen from 
the well-enumerated population of GH mem-
bers, the race, income, and educational profile 
of the control population was similar to that 
of other female western Washington State resi-
dents (Saunders et al. 2008), and serum PCB 
concentrations were similar to the U.S. female 
population of reproductive age (CDC 2001). 
The availability of detailed questionnaire infor-
mation enabled the adjustment for potential 
confounding effects. Furthermore, we con-
ducted analyses of individual PCB congeners 
in addition to ΣPCBs and estrogenic PCBs to 
facilitate comparison with other studies.
To improve the sensitivity of our study, 
we used a well-defined set of criteria to evalu-
ate the certainty of endometriosis diagnosis. 
Disease features and evidence were evaluated 
directly from medical records rather than rely-
ing on self-report. We excluded cases with-
out surgical confirmation of endometriosis, as 
well as those women with a previous history 
of surgically confirmed endometriosis.
We selected as controls a random sample 
of women from the GH population rather 
than a group of women who had undergone 
surgical evaluation and been diagnosed with 
other gynecological conditions. We made this 
choice because of the possibility that women 
with other gynecological conditions, many of 
which are estrogen related, may not be repre-
sentative of the population at risk in terms of 
their PCB exposure. If women had abnormally 
high PCB levels, the use of the control group 
could potentially mask any true association 
between PCB exposure and endometriosis.
One consequence of our choice was that 
some of our controls may have had undiag-
nosed endometriosis. The presence of undiag-
nosed, symptomatic endometriosis in the 
control group was likely to have been < 2%, 
resulting in a very small number of cases being 
misclassified as controls (Holt and Weiss 
2000). Partly to address this issue, we lim-
ited our case group to women with definite 
or probable endometriotic disease, and it is 
unlikely that participants with this extent of 
disease were included in the control group. To 
further address the issue, in one sub  analysis 
we excluded controls with endometriosis-
type symptoms. In that analysis we found no 
change in our effect estimates, suggesting that 
the potential presence of undiagnosed cases 
in our control group had little impact on the 
results of the analyses we present here.
The postdiagnostic assessment of exposure 
levels is a limitation that is characteristic of 
all retrospective case–control studies of blood 
biomarkers and chronic disease. If PCB con-
centrations are affected by the disease, meas-
ured exposure levels may not be representative 
of past exposure occurring during a postu  lated 
period of causation. Weight change, which 
may affect PCB levels, is not a typical symp-
tom of endometriosis onset; therefore, we do 
not consider this type of exposure misclassi-
fication to be likely. Although little informa-
tion existed at the time of this study as to diets 
that would be effective in preventing disease 
recurrence, cases may nonetheless have modi-
fied their dietary habits after diagnosis. If cases 
decreased their meat or fat intake as a result 
of their endometriosis diagnosis, then the 
PCB concentrations in our case population 
may be under  estimates of the true pre  diagnosis 
exposure levels. It is also possible that other 
unidentified behavioral changes may be made 
as a result of an endometriosis diagnosis; if 
these changes affect PCB levels, they may have 
impacted our study results. There is some evi-
dence from animal studies that exposure to 
high PCB concentrations can affect growth of 
endometrial cells (Johnson et al. 1997; Rier 
et al. 1993); although we cannot rule out a 
minimal association in our data, it is likely 
that exposure to higher concentrations than 
those observed in the present study would be 
required to have an appreciable impact on 
endometriosis risk if a causal association truly 
does exist. Taken in context with results of 
other recent North American studies, our find-
ings indicate that PCB concentrations con-
sistent within the range of exposure currently 
observed in western Washington State do not 
contribute meaningfully to endometrio  sis risk. 
If patterns of decreasing PCB body burden 
continue in the general U.S. population as they 
have since the PCB ban in 1976, our results 
suggest that environmental PCB exposure is 
likely too low to play a measurable role in the 
etiology of endometriosis. Further evalua  tion 
in population-based studies conducted in occu-
pational or environmental settings is needed to 
assess associations with higher PCB exposures.
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